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Essential thrombocytosis (ET) is clonal chronic myeloprolifertive disorder which 
originates from abnormality of a multipotent hematopoietic stem cell. 
It is characterized by an increased platelet count, megakaryocytic hyperplasia and by 
hemorrhagic or thrombotic tendency. Symptoms and signs may include weakness, 
headaches, paresthesias, bleeding, splenomegaly, and digital ischemia. ET patients 
showed equal or slightly shorter survival than age- and sex-matched healthy population. 
Major causes of death were  thrombotic and hemorrhagic complications or malignant 
progression due to both the natural history of the disease and, possibly, the use of 
chemotherapeutic agents. 
Diagnostic criteria for essential thrombocythemia were proposed in 2005 by the PVSG 
and demand diagnosis of exclusion. 
Myelosuppressive therapy to lower the platelet count usually consists of hydroxyurea, 
interferon alfa or anagrelide. Hydroxyurea is the most commonly used treatment, because 
of its efficacy, low cost and rare acute toxicity. Interferon alfa is a biological response 
modifier. It is not known to be teratogenic and does not cross the placenta, and is often 
the treatment of choice during pregnancy. Anagrelid suppresses bone marrow 
megakaryocytes by interfering with the maturation process and decreasing platelet 
production without affecting other blood cell lines. Low-dose aspirin may be used to control 
microvascular symptoms. 
Recommendations for management of patients with essential thrombocythemia were 
given by ASH. From a treatment standpoint, hydroxyurea is now confirmed to be the drug 
of choice for high-risk patients with essential thrombocythemia. Interferon alfa and 
anagrelide are reasonable second-line agents. Low-risk patients should receive low-dose 
aspirin alone. For the intermediate-risk patients, a consensus could not be reached on a 
recommendation for platelet-lowering treatment. Acta Medica Medianae 2008;47(3):51-55. 
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Introduction 
 
Essential thrombocythemia is chronic mye-
loproliferative disorder, involving clonal hematopo-
ietic stem cells abnormality. It is characterized by 
an increased platelet count megakaryocytic 
hyperplasia in bone marrow, and hemorrhagic 
and thrombotic tendency. 
Disease is rare (incidence 1:1000000). It 
occurs most often after the age of 50, although it 
can happen in the age between 2 and 90. 
Disorder occurs slightly more often in women. 
Etiology of disease is unknown. It occurs because 
of the abnormality of a multipotent hematopoietic 
stem cell or CFU-GEMM stem cell myeloid lines. 
Disease is characterized by highly increased platelet 
formation (up to 10 times more than normal) 
while their age is preserved, so their count in 
peripheral blood could be over 1000/mm
3, while 
formation of other blood cell lines is within 
normal range. Because of the increased platelet 
count, thromboembolic complications occur in 
venous and arterial blood vessels.  
Diagnostic criteria for essential thrombo-
cythemia are controversial, and universal agreement 
is lacking, thus diagnosis of essential thrombo-
cythemia is established by the method of 
exclusion. Version of PVSG diagnostic criteria for 
essential thrombocythemia is shown in Table 1.  
Molecular studies suggested new possibilities 
of diagnostic research. A molecular marker that 
can be applied to diagnostic evaluation is 
thrombopoietin receptor c-Mpl. Its reduction was 
discovered in essential thrombocythemia platelets. 
Studies have also indicated that percentage of 
megakaryocytes with Mpl expression in bone 
marrow provides a means of both distinguishing 
ET from reactive or secondary thrombocytosis 
and that it can also provide a means for 
prediction a tendency toward thrombosis as well 
as disease progression in polycythemia vera or 
idiopathic myelofibrosis (1,2). Modality  of  treatment  in  essential  thrombocythemia       Irena  Ćojbašić et al. 
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Table 1.Proposed diagnostic criteria for essential 
thrombocythemia (ET) 
 
A1  Platelet count > 600 × 109 /L for at least 2 
months 
A2  Acquired JAK2 mutation 
B1  No cause for a reactive thrombocytosis 
- e.g., normal inflammatory indices 
B2  No evidence of iron deficiency 
- stainable iron in the marrow or normal red cell 
mean corpuscular volumea 
B3  No evidence of PV 
- hematocrit < midpoint of normal range or 
normal red cell mass in presence of normal iron 
stores 
B4  No evidence of chronic myeloid leukemia 
- no Philadelphia chromosome or bcr-abl gene 
rearrangement 
B5  No evidence of myelofibrosis 
- no collagen fibrosis and ≤ grade 2 reticulin 
fibrosis (using 0–4 scale) 
B6  No evidence of a myelodysplastic syndrome 
- no significant dysplasia 
- no cytogenetic abnormalities suggestive of 
myelodysplasia 
Diagnosis of ET requires A1+A2+B3–6 (V617F-
positive ET) or A1+B1–6  
(V617F-negative ET). 
 
In over 50% of patients with essential 
thrombocythemia mutation V617F JAK has been 
found, which divides patients in to two different 
groups. V617F positive patients displayed 
significantly higher hemoglobin levels, neutrophil 
counts, bone marrow erythropoiesis and 
granulopoiesis, more venous thromboses and a 
higher incidence of polycythemic transformation 
as well as lower serum erythropoietin and ferritin 
levels. V617F-negative patients with essential 
thrombocythemia have more frequent cytogenetic 
abnormalities, hypercellular bone marrow with 
abnormal megakaryocyte morphology, PRV1 overe-
xpression, growth of erythropoietin-independent 
erythroid colonies, and a risk of myelofibrotic or 
leukemic transformation. These facts demand 
that essential thrombocythemia should be 
subclassified as either V617F-positive or V617F-
negative. Most recent studies have shown that 
there is no significant difference between V617F-
positive or V617F-negative essential thrombo-
cythemia regarding disease duration or frequency 
of disease transformation (3,4). Lower percentage 
of registered mutation-positive patients is the 
consequence of low method sensitivity and the 
fact that variable percentage of the granulocytes 
is derived from the malignant clone. In the case 
of JAK2 mutation, diagnosis of essential 
thrombocythemia demands that other myelo-
proliferative diseases are excluded, as well as 
reactive thrombocytosis and iron deficiency (5).  
The main causes of death of patients with 
essential thrombocythemia are thrombosis, 
hemorrhage, and progression to myelofibrosis or 
acute myelogenous leukemia. Myelosupressive 
therapy that prevents vascular events in essential 
thrombocythemia can by itself increase the risk 
of transformation to myelofibrosis or myeloid 
leukemia. Challenge in treatment of essential 
thrombocythemia is to prevent bleeding and 
thrombosis without increasing the risk (3).  
Vascular complications are the most common 
cause of morbidity and mortality in subjects 
suffering from ET, bearing in mind very low 
frequency of transformation to myelofibrosis (6-
10%) and acute leukemia. Because of that, 
studies describe essential thrombocythemia as 
“benign” disease and show that there is no 
significant decrease in life expectancy in patients 
with essential thrombocythemia in comparison to 
healthy population. Around 40% of patients show 
tendency towards thrombosis, while 60% show 
tendency towards bleeding. In one third of 
patients, functional vasomotor disorders occur 
(vascular headache, sight disorders, pains in 
palms and feet, distal paresthesis, akrocyanosis). 
Numerous risk factors for thrombosis have been 
identified. High risk for thrombosis is reported in 
patients over 60 years of age or with previous 
history of thrombosis. Significance of platelet 
count is less clear. Major hemorrhages have been 
more frequent in patients with platelet count 
higher than 1500×10
9/l. There is an increased     
risk for thrombosis in patients with platelet count 
higher than 1000×10
9/l when diagnosis is 
established or in patients with increased platelet 
count during therapy. Numerous other characte-
ristics can correlate with thrombotic 
complications. This includes clonal X chromosome 
inactivation, decrease of expression of MPL in 
bone marrow megakariocytes, overexpression of 
PRV1 in granulocytes of peripheral blood. The 
increased risk of thrombosis can be combined with 
antiphospholipid  antibodies, heterozygosity for 
factor V Leiden and numerous cardiovascular risk 
factors, such as hypertension, diabetes mellitus, 
smoking and hypercholesterolemia (6,7). 
 
Therapy 
 
The treatment of essential thrombocythemia 
is still an unsolved clinical issue. Epidemiological 
studies have shown that patients over 60 years 
of age or those with previous history of 
thrombosis are at high risk for thrombosis and 
should be treated with medications that decrease 
platelet count. At the same time, there is no 
correlation between platelet count and thrombosis 
in essential thrombocythemia, and, paradoxically, 
patients with extremely high platelet counts of 
1500×10
9 show more tendency towards bleeding, 
while patients with platelet counts less than 
600×10
9 show tendency towards thrombosis (8).  
Hydroxyurea is the most commonly used 
medication for reduction of platelet count. It 
belongs to the group of antimetabolic drugs since 
it inhibits deoxynucleotide sythesis and thus 
inhibits cell replications. Hydroxyurea is used as 
the first therapeutic line in high-risk patients 
because of its efficiency, low cost and rare acute 
toxicity. The most common side effects are leg 
ulcers and other changes on the skin (photo-
sensitivity and solar keratosis) and reversible 
suppression of bone marrow (9). A common concern Acta Medica Medianae 2008,Vol.47                       Modality of treatment in essential thrombocythemia   
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is whether hydroxyurea could be leukemogenic. 
Some studies have shown that 5-10% of patients 
treated with hydroxyurea develop AML/MDS. 
These studies have included small numbers of 
patients and many of them also received other 
cytoreductive drugs, so it remained unclear 
whether it was the drug effect or the consequence 
of the progression of disease. In contrast, 
nowadays, numerous new studies have shown 
that patients with essential thrombocythemia 
treated only with hydroxyurea have low incidence 
of AML/MDS i.e. they show that its leukemogenic 
potential is very low (3-4%) (10, 11). 
Interferon-α is myelosuppressive protein 
product, produced by recombinant DNA 
technology. The mechanism of antitumor activity 
is not quite clear, but it is thought that direct 
antiproliferative effect on malignant cells and 
modulation of host immune response probably 
have an important role.  
Italian and American researchers have 
shown their results with interferon-α in patients 
with essential thrombocythemia. A long-acting 
form of interferon was applied, which was 
administered once a week. The largest response 
was after 3 to 6 months since the start of therapy 
with global rate of response of 50% to 80%. 
Toxicity, usually WHO grade II, is expected 
proportionally to the dosage, but there are no 
evidence that interferon permanently damages 
the bone marrow (12).  
Interferon-α is effective in reduction of 
platelet count below 600×10
9/l in 90% of 
patients. Average dosage is 3 millions of unit per 
day. It is not know whether it is teratogenic or 
leukemogenic, but it has been proven that it does 
not pass the placenta, thus it is often the therapy 
of choice in pregnancy. Need for parenteral 
application and its side effects, especially flu-like 
symptoms, are important problems and lead to 
the cancellation of application of medication in a 
significant percentage of patients.  
Anagrelide is an imidazoquinazoline 
derivate which has been originally derived as 
inhibitor of aggregation of thrombocytes. Later, 
his efficiency has been detected in lowering the 
platelet count in 70 to 80% of patients in 
dosages lower than those that inhibit aggregation 
of thrombocytes. Around 10% of patients are 
completely refractory, probably because of inability 
to generate active metabolite of the medication. 
Anagrelide inhibits activity of anti-cyclic AMP 
phosphodiesterase. It selectively inhibits the 
maturation of megakariocytes with minimal effect 
or with no effect on other blood cell lines. It also 
acts as vasodilator, having a positive inotrope 
effect. PT-1 study has shown that anagrelide is 
not so effective and well tolerated as 
h y d r o x y u r e a ,  s o  i t  s h o u l d  n o t  b e  u s e d  a s  f i r s t  
therapeutic line in high risk patients (13). 
Up to now only two prospective randomized 
studies of treatment of patients with essential 
thrombocythemia have been done. The first 
study included 114 patients, older than 60 years 
of age or had one previously verified thrombosis. 
They were divided in two groups, one that has 
been treated with hydroxyurea and other without 
cytoreductive therapy. After a median follow-up 
of 27 months, thrombosis developed in 3.6% of 
treated patients as opposed to 24% of untreated 
patients which had one or more thrombotic events. 
Then, it was clearly shown for the first time that 
cytoreductive therapy reduced thrombotic events 
in patients with essential thrombocythemia (14). 
The second randomized study included over 
800 of high risk patients with essential 
thrombocythemia, which had previous thrombosis, 
age over 60 or platelet count of more than 
1000×10
9/l. Two groups of patients were 
compared, one that had been treated with 
hydroxyurea and aspirin and the other that had 
been treated with anagrelide and aspirin. The 
median follow-up was 39 months. The results 
showed several main differences between those 
two groups. The group treated with hydroxyurea 
and aspirin, as opposed to the group treated with 
anagrelide and aspirin, had greater frequency of 
arterial thrombosis, significant hemorrhages, 
myelofibrotic transformation and cancellation of 
treatment, but decrease of percentage of venous 
thromboembolism. Platelet count control and 
incidence of leukemia was similar in both groups (15).  
It is very informative to compare these 
results with Italian study. Statistical rate of the 
first thrombosis in two years was 4%, 8%, 26%, 
for the patients who were treated with hydroxyurea 
and aspirin, with anagrelide and aspirin, or got 
no cytoreductive therapy, respectively. Italian 
study has shown that percentage of venous 
thrombosis was significantly lower in the group 
treated with anagrelide and aspirin, as opposed 
to the partial prevention of arterial thrombosis. 
The frequency of venous thrombosis in untreated 
patients with high risk essential thrombocythemia 
is unknown, as it is not clear whether percentage 
is rising for the treatment with hydroxyurea and 
aspirin or decreasing for treatment with 
anagrelide and aspirin. Optimal treatment of 
patients with previous venous thrombosis depends 
on individual circumstances, bearing in mind that 
arterial thrombotic events are more than 3 times 
more frequent than venous thrombotic events in 
essential thrombocythemia. Researchers concluded 
that hydroxyurea and aspirin are superior in 
comparison with anagrelide and aspirin in patients 
with essential thrombocythemia that have high 
risk of vascular events, since that therapy leads 
to significant decrease of arterial and venous 
thrombosis (16). 
The study has also shown that platelet 
count control alone should not be taken as a 
measure of efficiency of treatment for essential 
thrombocythemia, since there is an increase of 
vascular events in the anagrelide group as 
opposed to the reduction of platelet count that 
has been similar to reduction in hydroxyurea 
group. Probable explanation for this discovery is 
widened myelosupressive activity of hydroxyurea 
that influences both leukocytes and erythrocytes. 
There is an ever increasing number of evidence 
that these cells play an important role in patho-
genesis of thrombosis in essential thrombocythemia.  
Anagrelide and low dosage of aspirin seem 
to have synergy effect in increase of the risk for Modality  of  treatment  in  essential  thrombocythemia       Irena  Ćojbašić et al. 
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hemorrhagic complications. Simultaneous admini-
stration of these two medications probably leads 
to inhibition of platelet function. To the contrary, 
combination of hydroxyurea and aspirin provides 
protection from thrombosis with a minimal risk of 
bleeding.  
Some studies have shown that progression 
to myelofibrosis is three times more often in the 
group with anagrelide compared to the group 
with hydroxyurea. The evolution to myelofibrosis 
is a part of the natural history of essential 
thrombocythemia and can be met in approxi-
mately 3% of patients after 5 years, 8% after 8 
years, 15% after 15 years. The risk of myelofibro-
sis can be distinguished by the basic characte-
ristic of the bone marrow. It is very low in the so-
called real essential thrombocythemia in which 
bone marrow does not have histopathological 
characteristics of myelofibrosis, and is higher 
when bone marrow shows prefibriotic stage of 
myelofibrosis. Transformation to acute myeloid 
leukemia has been found in similar numbers in 
group with hydroxyurea and in group with 
anagrelide.  
For now, hydroxyurea and aspirin should be 
standard therapy for patients with essential 
thrombocythemia, that have high risk of 
thrombosis.  
The largest last two trials about anagrelide 
for the treatment of essential thrombocythemia 
included more than 9000 patients each. Studies 
involved patients that were refractory and did not 
stand other therapy for lowering platelet count. 
Anagrelide proved to be efficient in lowering 
platelet count in more that 78% of patients (64% 
complete remission CR, 12% partial remission 
PR) in first, while there were 77% of responses in 
other study (66% CR, 11% PR). With daily dosage 
of 2.0 mg up to 2.5 mg, response time was average 
70 days in each study and without difference for 
patients with extreme thrombocytosis (platelet 
count larger than 1500×10
9/l). Reduction of 
platelet count was accompanied by decrease of 
thrombotic and hemorrhagic events. Side effects 
of the medication were headache, palpitations, 
diarrhea, edema, anemia and they led to the 
cancellation of treatment in about 25% of 
patients (17,18).  
New way in treatment of essential thrombo-
cythemia and other myeloproliferative diseases is 
opened by recent identification of mutation of 
JAK2 gene in majority of patients with polycythemia 
vera, and in around half of patients with essential 
thrombocythemia or myelofibrosis. Consequence 
of this mutation is constitutive tyrosine kinase 
activity of JAK2 that results in proliferation and 
survival of hematopoietic progenitor cells. New 
inhibitors of tyrosine kinase are developed with 
the aim to discover aimed therapy for this 
disease. 
Recommendation scheme of ASH (American 
Society of Hematologists) for treatment of 
essential thrombocythemia is shown in Table 2.  
Table 2. Recommendations of ASH for management of 
patients with essential thrombocythemia (ET) 
 
1.   All patients: 
•  manage reversible cardiovascular risk factors 
aggressively (e.g., smoking, hypertension, 
hypercholesterolemia, obesity. 
2.   High-risk patients (prior thrombosis or 
age > 60 years or platelets  
> 1500 × 109 /L): 
• low-dose aspirin plus hydroxyurea (anagrelide or 
interferon-α second line. 
3.   Intermediate-risk patients (age 40–60 years, 
no high-risk features): 
•  either enter into randomized trial (e.g., PT-1 
intermediate risk arm) 
• or low-dose aspirin (consider cytoreduction if other 
cardiovascular risk factors present) 
4.   Low-risk patients (age < 40 years and no high-
risk features): 
• low dose aspirin 
 
Up to date studies have shown that 
hydroxyurea should be first therapeutic line for 
majority of patients with high risk disease. 
Interferon-α and anagrelide are reserved as 
second therapeutic line. Decision whether to use 
aspirin demands potential risk and benefits 
assessment for each patient. Optimal treatment 
of patient with previous venous thrombosis would 
depend of individual circumstances, bearing in 
mind that arterial thrombotic events are more 
than three times more often than venous 
thrombosis in essential thrombocythemia. Also, 
there is a general consensus that patients with 
low risk of thrombotic events (younger than 40, 
without high risk characteristics), should get only 
low dosages of aspirin. For medium risk patients, 
(aged between 40 and 60, without high risk 
characteristics), there is no universal guide for 
therapy since it is not clear whether 
cytoreduction is useful. There are 
recommendations that such patients should be 
included in randomized studies such as 
intermediate risk PT-1 (hydroxyurea and aspirin 
versus aspirin only). However, patients aged 
between 40 and 60 years with high risk 
characteristics (platelet count larger than 
1000×10
9/l, family thrombophilia or present 
cardiovascular risk factors) should be treated 
with cytoreductive therapy. 
In addition, there are guidelines for the 
treatment of essential thrombocythemia in 
pregnancy. It is advisable to limit the usage of 
platelet-lowering agents in patients considered to 
be at high risk for thrombosis, and partially in 
patients with history of previous thrombosis or 
fetal loss. Anagrelide and hydroxyurea should be 
avoided because of the possibility of teratogenic 
effects, although there have been reports of 
normal pregnancies despite exposure to 
hydroxyurea. Interferon-α is generally regarded 
as the treatment of choice and should be 
combined with heparin in patients particularly at 
high risk, with treatment continuing for several 
weeks postpartum.  Acta Medica Medianae 2008,Vol.47                       Modality of treatment in essential thrombocythemia   
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MODALITY OF TREATMENT IN ESSENTIAL THROMBOCYTHEMIA 
 
Irena Ćojbašić i Lana Mačukanović-Golubović 
 
 
Esencijalna trombocitemija (ET) je hronično mijeloproliferativno oboljenje koje nastaje 
zbog poremećaja multipotentne matične ćelije hematopoeze. 
Karakteriše se porastom broja trombocita, hiperplazijom megakariocitne loze u kostnoj 
srži, sklonošću ka krvarenju i trombozama. Simptomi i znaci uključuju slabost, glavobolju, 
parestezije, krvarenje, splenomegaliju i digitalnu ishemiju. Bolesnici sa esencijalnom 
trombocitemijom imaju isto ili nešto kraće preživljavanje nego zdrava populacija istih 
godina i pola. Glavni razlog smrti su trombotične i hemoragične komplikacije ili 
transformacija bolesti, bilo kao prirodni tok bolesti ili kao posledica upotrebe citostatika. 
Dijagnostički kriterijumi za esencijalnu trombocitemiju su predloženi 2005. godine od 
strane PVSG i zahtevaju dijagnozu isključivanjem.  
Mijelosupresivna terapija za smanjenje broja trombocita sastoji se od hidroksiureje, 
interferona alfa ili anagrelida. Hidroksiureja je najšire korišćen lek, zbog svoje efikasnosti, 
niske cene i retke akutne toksičnosti. Interferon alfa je modulator biološkog odgovora. Nije 
poznato da je teratogen i ne prolazi kroz placentu pa je često tretman izbora tokom 
trudnoće. Anagrelid suprimira megakariocite kostne srži remeteći proces sazrevanja i 
smanjujući produkciju trombocita, bez efekta na druge ćelijske linije. Niske doze aspirina 
mogu biti korišćene u kontroli mikrovaskularnih simptoma. 
Preporuke za lečenje bolesnika sa esencijalnom trombocitemijom su date od strane 
ASH. Sa stanovišta terapije, hidroksiureja je sada potvrđena kao lek izbora za lečenje 
visoko-rizičnih bolesnika sa esencijalnom trombocitemijom. Interferon alfa i anagrelid su 
prihvaćeni kao lekovi druge linije. Nisko-rizični bolesnici trebalo bi da dobijaju samo niske 
doze aspirina. Za bolesnike sa intermedijarnim rizikom nije postignut koncenzus o 
preporukama za trombocitoreducirajući tretman. Acta Medica Medianae 2008;47(3):51-55. 
 
Ključne reči: esencijalna trombocitemija, preporuke, tretman 